Cancer Therapy-Related Cardiac Dysfunction, Risk Stratification, and Outcomes in ICOP Registry: First Data from the Arabian Middle East Region

Read full text Summarise with VIRAT
Authors: Hasan Ali Farhan, Ali Abdulhameed Ali, Israa Fadhil Yaseen
Cited by: 0
References: 13

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Despite the evolving cardio-oncology discipline globally, data regarding cardio-oncology in the Arabian Middle East is lacking.The latter issue may be explained by the absence of cardiooncology clinics in the region over the last few years.In general, data from the Middle East in the field of cardiology were limited, and Iraq was among the first four countries in the region with the lowest publications; only 67 publications until 2015 (1).In 2020, a cardio-oncology clinic was established in Iraq, and two prospective studies were conducted: Iraqi Cardio-Oncology Program (ICOP) and ICOP-Pharm registries (2).The current study will be the first and largest published data in the field of cardio-oncology from the Arabian Middle East region to identify the incidence of cancer therapy-related cardiovascular toxicities (CTR-CVT), including early cancer therapy-related cardiac dysfunction (CTRCD), with the mean time of left ventricular ejection fraction (LVEF) recovery.CTR-CVT is defined as any cardiovascular adverse events induced by cancer therapy, for example, CTRCD, myocarditis, hypertension, etc. (3) CTRCD is the negative effect of cancer therapy on the heart structure and/or function, leading to either asymptomatic or symptomatic heart failure (3).ICOP registry, a prospective observational study, was conducted at the first cardiooncology clinic in Iraq between December 2020 and December 2022.All patients attending the clinic were enrolled in the study.The study was approved by the National Research Ethics Committee.

Fields of Study & Subjects

Chemotherapy-induced cardiotoxicity and mitigation Cardiac tumors and thrombi Cardiovascular Function and Risk Factors

Publication details

Journal / source
Global Heart
Volume
21
Issue
1
Pages
30–30
Publication date
27 March 2026
Language
EN